What is Roth Capital’s Estimate for Clene FY2027 Earnings?

Clene Inc. (NASDAQ:CLNN) – Equities researchers at Roth Capital upped their FY2027 earnings estimates for shares of Clene in a report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $6.41 for the year, up from their previous estimate of $6.30. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s FY2028 earnings at $9.04 EPS and FY2029 earnings at $12.47 EPS.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%.

Several other analysts also recently commented on CLNN. D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Clene in a research report on Monday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Clene currently has a consensus rating of “Buy” and a consensus target price of $55.25.

Clene Stock Performance

Shares of NASDAQ CLNN opened at $3.18 on Wednesday. The stock has a market cap of $26.48 million, a price-to-earnings ratio of -0.60 and a beta of 0.27. Clene has a fifty-two week low of $3.09 and a fifty-two week high of $9.20. The firm’s 50-day simple moving average is $4.46 and its 200 day simple moving average is $4.87.

Hedge Funds Weigh In On Clene

Hedge funds have recently modified their holdings of the company. Fullcircle Wealth LLC bought a new position in shares of Clene in the fourth quarter valued at approximately $69,000. SBI Securities Co. Ltd. bought a new stake in Clene during the fourth quarter worth $69,000. Renaissance Technologies LLC purchased a new position in Clene in the fourth quarter worth $96,000. Geode Capital Management LLC grew its stake in Clene by 52.9% in the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the period. Finally, Parsons Capital Management Inc. RI purchased a new stake in shares of Clene during the 4th quarter valued at $194,000. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.